Nevirapine extended-release formulation tablets in HIV-1-infected children--long-term follow-up.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 25917636.
- Also identified by DOI 10.1093/cid/civ340.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In the optional extension of clinical trial 1100.1518 39/40, human immunodeficiency virus-infected patients (aged 3 to <18 years) received ≥48 weeks of treatment with extended-release nevirapine. By last visit, all patients had undetectable viral loads and no new safety signals, demonstrating the safety and efficacy of a once-daily antiretroviral regimen.
Medical subject headings
- Anti-HIV Agents
- HIV Infections
- Nevirapine